日本：签署四倍于人口的疫苗预购协议？

▲全球视野 本土思考

由于日本本土疫苗仍处于开发第二阶段，这一举动受到称赞。

在一项向所有居民免费提供疫苗的法案之后，日本已与跨国制药公司签署了多项协议，以采购足够数量的COVID-19疫苗，其预订量超过其实际人口的四倍。

GlobalData对这一举动表示赞赏，认为这是一个明智的策略，因为该国的本地疫苗仍处于开发的第二阶段，而且它签署的一些疫苗可能会在临床试验中失败，或者这些疫苗可能需要超过一剂。

GlobalData的药业分析师表示，根据目前的临床发展情况，本土疫苗可能至少要到2022年才能在该国使用，因为它落后于全球领先的西方国家已经批准的疫苗。

该分析师补充说：“考虑到疫苗开发的困难，日本正在采取从不同公司购买疫苗的战略方法，即使国内疫苗的开发出现任何失败，也允许居民完全接种疫苗。”

目前，有大阪大学和国立传染病研究所等17个日本组织致力于COVID-19疫苗的开发，并且有两家日本制药公司处于疫苗开发的第二阶段。＊

japan signs deals for vaccine preorders four times the population

The move was lauded as local vaccines remain in Phase II stage.

Japan has signed multiple deals with multinational pharma firms to procure enough COVID-19 vaccine doses with pre-orders exceeding four times of its actual population, following a bill giving free vaccines to all its residents.

GlobalData lauded this move, viewing it as a wise strategy as the country’s local vaccines are still at Phase II stage of development, and some of the vaccines it signed for could fail in clinical trials or the vaccines may require more than one dose.

Based on the current clinical development, indigenous vaccines may not be available in the country at least until 2022, as it lags global-front runners with vaccines that are already approved in western nations, said GlobalData’s pharma analyst Bhavani Nelavelly.

“Considering the difficulty in vaccine development, Japan is using the strategic approach of getting vaccines from different companies, which allows complete vaccination of residents even if there are any development failures for domestic vaccines,” Nelavelly added.

Currently, there are 17 Japanese organizations, including Osaka University and National Institute of Infectious Diseases, working on COVID-19 vaccine development, and there are the two Japanese pharmas in Phase II stage of vaccine development.